Dr. Qiao Li 李俏
Chief Physician
Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences (National Cancer Center), Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical treatment of breast cancer, gastrointestinal tumors, and lung cancer. Focuses on chemotherapy, endocrine therapy, targeted therapy, and immunotherapy for breast cancer.
Dr. Li holds a doctoral degree from Peking Union Medical College’s eight-year clinical medicine program and is a Master’s supervisor. A visiting scholar at MD Anderson Cancer Center, Dr. Li leads clinical research on new anti-cancer drugs and has published in journals including the Journal of Clinical Oncology.
Professional roles
- Vice Chair, Youth Committee of the Breast Cancer Professional Committee, Chinese Research Hospital Association
- Standing Committee Member, Youth Academic Professional Committee, Beijing Society for Prevention and Treatment of Breast Diseases
- Reviewer, JCO Chinese Edition
- Reviewer, Chinese Journal of Breast Disease (Electronic Edition)
Name order: in Chinese the family name comes first (Li Qiao). Papers usually list the name as Qiao Li or Li Q.
Selected publications
104 papers on PubMed matched by name and affiliation; 19 as first or senior author since 2016. Most recent first- or senior-author papers:
- Breast Cancer (Dove Med Press), 2026 (senior author): Efficacy, Safety, and Prognostic Factors of Dalpiciclib Combined with Endocrine Therapy After Progression on CDK4/6 Inhibitors in Patients with HR+/HER2- Advanced Breast Cancer: A Retrospective Study. PubMed 42109311
- BMC Med, 2026 (senior author): Mitoxantrone hydrochloride liposome (Lipo-MIT) combined with capecitabine in HER2-negative advanced breast cancer: a dose-escalation, phase I study. PubMed 42050512
- Oncologist, 2026 (senior author): Efficacy of neoadjuvant endocrine therapy with CDK4/6 inhibitors in locally advanced breast cancer. PubMed 41649465
- Breast Cancer (Dove Med Press), 2025 (senior author): Safety Profile and Predictors of Adverse Events of Incadronate Disodium in Treating Breast Cancer Patients with Bone Metastases: A Retrospective Study. PubMed 40861833
- BMC Cancer, 2025 (senior author): Anlotinib in combination with metronomic chemotherapy in HER2-negative metastatic breast cancer: an observational and retrospective study. PubMed 39754078
- BMC Cancer, 2024 (senior author): Pyrotinib combined with metronomic etoposide in heavily pretreated HER2-positive metastatic breast cancer: a single-arm, phase II study. PubMed 39425028
- Cancer Innov, 2024 (first author): Inetetamab combined with sirolimus and chemotherapy for the treatment of HER2-positive metastatic breast cancer patients with abnormal activation of the PI3K/Akt/mTOR pathway after trastuzumab treatment. PubMed 39301201
- Ther Adv Med Oncol, 2024 (senior author): Inetetamab-based therapy in real-world treatment patterns with HER2-positive advanced breast cancer patients: a retrospective single-center study. PubMed 39257649
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion